These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8268880)

  • 21. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of renin-guided treatment of hypertension.
    Smith SM; Campbell JD
    Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost-effectiveness analysis on compound anti-hypertensive tablets for primary hypertension].
    Wu YQ; Hu YH; Ren T; Wu T; Tao QS; Qin XY; Zhang Y; Zhan SY; Cao WH; Li LM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Apr; 29(4):383-6. PubMed ID: 18843999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life and cost-effectiveness in the treatment of hypertension.
    Wiklund I
    J Clin Pharm Ther; 1994 Apr; 19(2):81-7. PubMed ID: 8071397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-benefit aspects of treatment of hypertension in the elderly.
    Lindholm LH; Johannesson M
    Blood Press Suppl; 1995; 3():11-4. PubMed ID: 8535536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating mild to moderate hypertension: cost-effectiveness and policy implications.
    Kawachi I; Malcolm LA
    J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S126-8. PubMed ID: 1708013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.
    Stafilas PC; Sarafidis PA; Lasaridis AN; Aletras VH; Niakas DA
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1233-40; discussion 1241-2. PubMed ID: 16182115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness issues in hypertension control.
    Schueler K
    Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of intensive hypertension control in China.
    Xie X; He T; Kang J; Siscovick DS; Li Y; Pagán JA
    Prev Med; 2018 Jun; 111():110-114. PubMed ID: 29525577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of combination therapy. Based on a presentation by Daniel Hilleman, PharmD.
    Am J Manag Care; 1999 Jun; 5(7 Suppl):S449-53; discussion S453-5. PubMed ID: 10538853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Grover SA; Coupal L; Zowall H
    Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment.
    van Schoonhoven AV; van Asselt ADI; Tomaszewski M; Patel P; Khunti K; Gupta P; Postma MJ
    Hypertension; 2018 Nov; 72(5):1117-1124. PubMed ID: 30354817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost effectiveness of hypertension treatment in Sweden.
    Johannesson M
    Pharmacoeconomics; 1995 Mar; 7(3):242-50. PubMed ID: 10155314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of cost-effectiveness analyses of hypertension treatment.
    Johannesson M; Jönsson B
    Pharmacoeconomics; 1992 Apr; 1(4):250-64. PubMed ID: 10147016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care.
    Kulchaitanaroaj P; Brooks JM; Chaiyakunapruk N; Goedken AM; Chrischilles EA; Carter BL
    J Hypertens; 2017 Jan; 35(1):178-187. PubMed ID: 27684354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.